HomeMy WebLinkAboutMINUTES - 07102012 - C.61RECOMMENDATION(S):
Approve and authorize the Health Services Director, or his designee, to execute, on behalf of the County, Contract
#26-654-7 with Bay Area Tumor Institute, a non-profit corporation, in an amount not to exceed $250,000, to provide
pharmaceutical drug recovery reimbursement services, for the period from August 1, 2012 through July 31, 2013.
FISCAL IMPACT:
This is a contingency fee contract. Contractor receives a percentage of the amount it collects on behalf of the County.
No rate increase included in this Contract. No rate increase.
BACKGROUND:
On September 14, 2010, the Board of Supervisors approved Contract #26-654-3 (as amended by #26-654-5 and
#26-654-6) with Bay Area Tumor Institute, for the period from August 1, 2011 through July 31, 2012, for the
provision of pharmaceutical drug recovery reimbursement services of products provided to indigent or unfunded
patients.
Approval of Contract #26-654-7 will allow the Contractor to continue providing services through July 31, 2013.
APPROVE OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR RECOMMENDATION OF BOARD COMMITTEE
Action of Board On: 07/10/2012 APPROVED AS RECOMMENDED OTHER
Clerks Notes:
VOTE OF SUPERVISORS
AYE:John Gioia, District I Supervisor
Candace Andersen, District II
Supervisor
Mary N. Piepho, District III
Supervisor
Karen Mitchoff, District IV
Supervisor
Federal D. Glover, District V
Supervisor
Contact: Kathryn Leppert,
313-6513
I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board
of Supervisors on the date shown.
ATTESTED: July 10, 2012
David Twa, County Administrator and Clerk of the Board of Supervisors
By: Carrie Del Bonta, Deputy
cc: Tasha Scott, Demetria Gary
C. 61
To:Board of Supervisors
From:William Walker, M.D., Health Services Director
Date:July 10, 2012
Contra
Costa
County
Subject:Contract #26-654-7 with Bay Area Tumor Institute
CONSEQUENCE OF NEGATIVE ACTION:
If this contract is not approved, County will not be receiving reimbursement from pharmaceutical manufacturers of
products provided to indigent or unfunded patients.
CHILDREN'S IMPACT STATEMENT:
Not applicable.